Content about Specialty pharmacy

March 4, 2014

Drug Channels on Tuesday sized up the specialty pharmacy market. Last year specialty drugs accounted for 22% of all pharmacy revenue, and 63% of the specialty business is dispensed by three companies: Express Scripts, CVS Caremark and Walgreens.

PHILADELPHIA — Drug Channels on Tuesday sized up the specialty pharmacy market. Last year specialty drugs accounted for 22% of all pharmacy revenue, and 63% of the specialty business is dispensed by three companies: Express Scripts, CVS Caremark and Walgreens. According to Drug Channels estimates, the specialty pharmacy market generated $63.2 billion in 2013. 

March 4, 2014

Physicians Interactive, a provider of online and mobile clinical resources and solutions for healthcare professionals, and McKesson Patient Relationship Solutions, a provider of pharmaceutical manufacturer-sponsored patient adherence programs, on Tuesday announced a collaboration to jointly deliver Coupons on Demand.

READING, Mass. — Physicians Interactive, a provider of online and mobile clinical resources and solutions for healthcare professionals, and McKesson Patient Relationship Solutions, a provider of pharmaceutical manufacturer-sponsored patient adherence programs, on Tuesday announced a collaboration to jointly deliver Coupons on Demand. The new solution is designed to provide clinicians convenient access to medication cost-savings offers and adherence support through a patented web-based platform.  

March 3, 2014

Cardinal Health Specialty Solutions on Monday announced the acquisition of privately held Sonexus Health, a Dallas-based company that offers a range of patient access and specialty commercialization services.

DUBLIN, Ohio — Cardinal Health Specialty Solutions on Monday announced the acquisition of privately held Sonexus Health, a Dallas-based company that offers a range of patient access and specialty commercialization services.

March 3, 2014

Diplomat Pharmacy on Friday announced it will be hosting college students from across the nation this week.

FLINT, Mich. — Diplomat Pharmacy on Friday announced it will be hosting college students from across the nation this week. Students from as far away as New Mexico State will be participating in an expanded version of Diplomat’s Alternative Spring Break program that kicked off Monday. 

Also serving with New Mexico State will be students and staff members from Michigan State, Virginia Tech and the University of Michigan-Ann Arbor.

February 28, 2014

Lupin announced that it received approval from the Food and Drug Administration for rifabutin capsules USP, 150-mg, a generic version of Pharmacia and Upjohn Company's Mycobutin capsules.

MUMBAI and BALTIMORE — Lupin on Wednesday announced that it received approval from the Food and Drug Administration for rifabutin capsules USP, 150 mg — a generic version of Pharmacia and Upjohn Company's Mycobutin capsules. The company's U.S. subsidiary will begin marketing the product soon.

The drug is used for the prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection. Mycobutin capsules had annual sales of $18.6 million in the United States, according to IMS MAT.

 

February 25, 2014

The Food and Drug Administration has approved Myalept (metreleptin for injection) to treat complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy, a condition associated with a lack of fat tissue.

SILVER SPRING, Md. — The Food and Drug Administration has approved Myalept (metreleptin for injection) to treat complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy, which is a condition associated with a lack of fat tissue.

February 21, 2014

As part of a study conducted with the University of Arizona, Avella Specialty Pharmacy proved the value of pharmacist intervention in improving patient outcomes, at least in renal transplant patients, to the tune of $27,852 per month, Avella announced.

PHOENIX — As part of a study conducted with the University of Arizona, Avella Specialty Pharmacy proved the value of pharmacist intervention in improving patient outcomes, at least in renal transplant patients, to the tune of $27,852 per month, Avella announced Thursday. The study found that participants in the intervention group had a statistically significant improvement in adherence rates over patients in the control group who did not have a contract or receive support to ensure adherence to their monthly medication therapy.

February 20, 2014

In most exchange plans, consumers will face paying a percentage of the costs — often called co-insurance — rather than fixed-dollar co-payments for many specialty medications used to treat rare and complex diseases.

WASHINGTON — In most exchange plans, consumers will face paying a percentage of the costs — often called co-insurance — rather than fixed-dollar co-payments for many specialty medications used to treat rare and complex diseases. According to a new Avalere Health analysis, some plans require enrollees to pay 50% of the specialty drug’s cost. If exchange plans use coinsurance for specialty medications, patients may incur several thousands of dollars of cost-sharing for high-cost drugs before reaching the out-of-pocket maximum.

February 20, 2014

The Food and Drug Administration recently approved two "robotic pills," or pills that place an image camera or ingestible sensors into the gastrointestinal tract, according to a report published earlier this week by the Wall Street Journal.

NEW YORK — The Food and Drug Administration recently approved two "robotic pills," or pills that place an image camera or ingestible sensors into the gastrointestinal tract, according to a report published earlier this week by the Wall Street Journal

Other robotic pills still in development include one backed by Google — a pill that would replace injectable drugs, the report noted. 

February 19, 2014

The N.E.W. Life Center, a Flint-based ministry supported by Diplomat Pharmacy, on Tuesday expanded its facility, the specialty retailer announced.

FLINT, Mich. — The N.E.W. Life Center, a Flint-based ministry supported by Diplomat Pharmacy, on Tuesday expanded its facility, the specialty retailer announced. 

The community program is based out of the former St. Luke’s Catholic Church on Lawndale Avenue. N.E.W. Life Center founded N.E.W. Life Enterprises, a business that produces scrubs and hospital gowns for use in medical facilities along with other sewn items. The renovation and expansion will house work stations for the seamstresses.

February 19, 2014

The Food and Drug Administration announced that it has approved Northera capsules (droxidopa) for the treatment of neurogenic orthostatic hypotension.

SILVER SPRING, Md. — The Food and Drug Administration announced that it has approved Northera capsules (droxidopa) for the treatment of neurogenic orthostatic hypotension.

NOH is a rare, chronic drop in blood pressure upon standing that's associated with Parkinson's disease, multiple-system atrophy and pure autonomic failure. Symptoms include dizziness, lightheadedness, blurred vision, fatigue and fainting when a person stands.

February 19, 2014

The results of the 2013 BPS specialty certification and recertification exams were announced Tuesday by the Board of Pharmacy Specialties, the post-licensure certification organization serving the pharmacy profession.

WASHINGTON — The results of the 2013 BPS specialty certification and recertification exams were announced Tuesday by the Board of Pharmacy Specialties, the post-licensure certification organization serving the pharmacy profession.   

February 18, 2014

Actavis and Forest Labs. announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock).

DUBLIN — Actavis and Forest Labs. on Tuesday announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at approximately $25 billion, or $89.48 per Forest share ($26.04 in cash and 0.3306 Actavis shares for each share of Forest common stock). The per share consideration represents a premium of approximately 25% per share over Forest’s stock price, and a premium of approximately 31% over Forest’s 10-day volume weighted average stock price, as of the close of trading on Feb.

February 18, 2014

“No one gets paid unless patients improve adherence.”

“No one gets paid unless patients improve adherence.”

That’s what Aaron McKethan, SVP of strategy and business development for RxAnte, had to say in a Jan. 13 article on Forbes.com, “A digital health acquisition to watch.” The story focused largely on RxAnte’s recent acquisition by Millennium Laboratories in December — which the author described as a “little-known, private equity-backed urine drug testing company” — and the technology it uses to improve patient adherence.

February 18, 2014

Diplomat Specialty Pharmacy on Monday announced that it has initiated a content partnership with the National Association of Specialty Pharmacy.

FLINT, Mich. — Diplomat Specialty Pharmacy on Monday announced that it has initiated a content partnership with the National Association of Specialty Pharmacy.

The new partnership will support Diplomat’s recently launched web platform, diplomat.is, and its goal to be a leading resource for specialty pharmacy. Additionally, the partnership will further establish NASP’s position as a leading voice in specialty pharmacy and clinical news.

February 18, 2014

Hy-Vee announced that it has entered into an agreement to purchase Amber Pharmacy, a specialty pharmacy solutions provider based in Omaha, Neb.

WEST DES MOINES, Iowa — Hy-Vee on Monday announced that it has entered into an agreement to purchase Amber Pharmacy, a specialty pharmacy solutions provider based in Omaha, Neb. Hy-Vee and Amber Pharmacy have been partners in Hy-Vee Pharmacy Solutions since 2010. This acquisition allows Hy-Vee to expand its current specialty pharmacy business, providing customers with increased specialty options, access and affordability.

February 18, 2014

Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

BASEL, Switzerland — Novartis on Monday announced that it is broadening its cancer immunotherapy research program with the acquisition of CoStim Pharmaceuticals, a Cambridge, Mass.-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer.

February 18, 2014

The Food and Drug Administration has approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome), which is a rare disease caused by a deficiency in N-acetylgalactosamine-6-sulfate sulfatase (GALNS).

SILVER SPRING, Md. — The Food and Drug Administration has approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome), which is a rare disease caused by a deficiency in N-acetylgalactosamine-6-sulfate sulfatase (GALNS).

February 18, 2014

With new advances in treatment therapy now available for hepatitis C patients, Walgreens announced it is expanding access to Walgreens Connected Care hepatitis C program through its more than 100 hepatitis C-specialized pharmacies.

DEERFIELD, Ill. — With new advances in treatment therapy now available for hepatitis C patients, Walgreens on Monday announced it is expanding access to Walgreens Connected Care hepatitis C program through its more than 100 hepatitis C-specialized pharmacies. Walgreens Connected Care is an education and support plan designed to help patients achieve a sustained virologic response and improved quality of life through medication adherence. 

February 13, 2014

Janssen Biotech announced that the Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy.

HORSHAM, Pa. — Janssen Biotech on Wednesday announced the Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Imbruvica was first approved in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Both indications are based on an overall response rate. An improvement in survival or disease-related symptoms has not been established.

February 13, 2014

Teva Pharmaceutical Industries announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

JERUSALEM — Teva Pharmaceutical Industries on Thursday announced that the Food and Drug Administration has granted full approval of Synribo (omacetaxine mepesuccinate) for injection.

The drug is indicated for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance and/or intolerance to two or more tyrosine kinase inhibitors.

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

DUBLIN — Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price of $10.62 per share for Cadence Pharmaceuticals.

February 11, 2014

The Generic Pharmaceutical Association announced its support of Georgia SB 370, introduced by pharmacist and Sen. Buddy Carter, R-Ga. District 1, because it will allow unimpeded patient access to interchangeable biologics.

WASHINGTON — The Generic Pharmaceutical Association on Tuesday announced its support of Georgia SB 370, introduced by pharmacist and Sen. Buddy Carter, R-Ga. District 1,  because it will allow unimpeded patient access to interchangeable biologics. The bill mirrors current pharmacy practice for interchangeable generic substitution language, and is aligned with Food and Drug Administration definitions, the association noted.

February 11, 2014

The Pharmacy Benefit Management Institute recently released its Specialty Drug Benefit Report, sponsored by Walgreens Specialty Pharmacy.

PLANO, Texas — The Pharmacy Benefit Management Institute recently released its Specialty Drug Benefit Report, sponsored by Walgreens Specialty Pharmacy. The 2014 edition highlights trends important to specialty pharmacy, including emerging cost-control strategies and challenges affecting benefit design and patient care. 

February 11, 2014

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists’ training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise, the retailer announced Tuesday.

DEERFIELD, Ill. — In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists’ training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise, the retailer announced Tuesday.